Role of human cytochrome P450 3A4 in the metabolism of DA–8159, a new erectogenic

Reference

• AMAKYE, D., WARD, J., BRYSON, S. and HAN, K., 2004, DA-8159—phase I studies to investigate the safety and pharmacokinetics in healthy male Caucasian subjects. Clinical Pharmacology CI Therapeutics, 75, 86.
   Web of Science ®Google Scholar
• ARLOTTO, M. P., TRANT, J. M. and ESTABROOK, R. W., 1991, Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods in Enzymology, 206, 454–462.
   PubMed Web of Science ®Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica, 25, 261–270.
   PubMed Web of Science ®Google Scholar
• BOEK-DOHALSKA, L., HODEK, P., SULC, M. and StIBOROVA, M., 2001, a-naphthofiavone acts as activator, and reversible or irreversible inhibitor of rabbit microsomal CYP3A6. Chemico-Biological Interactions, 138, 85–106.
   PubMed Web of Science ®Google Scholar
• BOURRIE, M., MEUNIER, V., BERGER, Y. and FABRE, G., 1996, Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics, 277, 321–332.
   PubMed Web of Science ®Google Scholar
• CHoi, S. J., J1, H. Y., LEE, H. Y., KIM, D. S., KIM, W. B. and LEE, H. S., 2002, In vitro metabolism of a novel phosphodiesterase-5 inhibitor DA-8159 in rat liver preparations using liquid chromatography/electrospray mass spectrometry. Biomedical Chromatography, 16, 395–399.
   Google Scholar
• CRESPI, C. L., CHANG, T. K. and WAXMAN, D. J., 1998, High-performance liquid chromatographic analysis of CYP2C8-catalyzed paclitaxel 6a-hydroxylation. Methods in Molecular Biology, 107, 123–127.
   PubMedGoogle Scholar
• DIERKS, E. A., STAMS, K. R., Lim, H. K., CORNELIUS, G., ZHANG, H. and BALL, S. E., 2001, A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism CI Disposition, 29, 23–29.
   PubMed Web of Science ®Google Scholar
• EAGLING, V. A., TJIA, J. F. and BACK, D. J., 1998, Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. British Journal of Clinical Pharmacology, 45, 107–114.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., KIM, D. H. and IwAsiou, M., 1991, Role of human cytochrome P450 HE1 in the oxidation of several low molecular weight cancer suspects. Chemical Research in Toxicology, 4, 168–179.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1999, Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1–117.
   PubMed Web of Science ®Google Scholar
• GIBSON, G. G., PLANT, N. J., SWALES, K. E., AYRTON, A. and EL-SANKARY, W., 2002, Receptor-dependent transcriptional activation of CYP3A genes: induction mechanisms, species differences and interindividual variation in man. Xenobiotica, 32, 165–206.
   Google Scholar
• HYLAND, R., ROE, E. G. H., JONES, B. C. and SMITH, D. A., 2001, Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. British Journal of Clinical Pharmacology, 51, 239–248.
   Google Scholar
• KIM, J., KIM, S. J., J1, H. Y., PT.', J. K., LEE, S. S., KIM, D. S., Yoo, M., KIM, W. B. and LEE, H. S., 2003, Simultaneous determination of a new phosphodiesterase-5 inhibitor DA-8159 and its active metabolite in human plasma by high performance liquid chromatography with tandem mass spectrometry. Chromatographia, 57, 447–450.
   Google Scholar
• KRONBACH, T., 1991, Bufuralol, dextrmethorphan and debrisoquine as prototype substrates for human P45011D6. Methods in Enzymology, 206, 509–517.
   PubMed Web of Science ®Google Scholar
• LILLIBRIDGE, J. H., LIANG, B. H., KERR, B. M., WEBBER, S., QUART, B., SHETTY, B. and LEE, C. A., 1998, Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metabolism & Disposition, 26, 609–616.
   PubMed Web of Science ®Google Scholar
• LEEMANN, T., TRANSON, C. and DAYER, P., 1993, Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sciences, 52, 29–34.
   PubMed Web of Science ®Google Scholar
• MERRY, C., BARRY, M. G., RYAN, M., TPA, J. F., HENNESY, M., EAGLING, V. A., MULCAHY, F. and BACK, D. J., 1999, Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS, 13, F101—F107.
   Web of Science ®Google Scholar
• MUIRHEAD, G. J., WULFF, M. B., FIELDING, A., KLEINERMANS, D. and Buss, N., 2000, Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. British Journal of Clinical Pharmacology, 50, 99–107.
   PubMed Web of Science ®Google Scholar
• MUIRHEAD, G. J., FAULKNER, S., HARNESS, J. A. and TAUBEL, J., 2002, The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil citrate in healthy volunteers. British Journal of Clinical Pharmacology, 53, 37S–43S.
   Google Scholar
• OH, T. Y., KANG, K. K., AHN, B. 0., Yoo, M. and KIM, W. B., 2000, Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Archives of Pharmacal Research, 23, 471–476.
   Google Scholar
• PERLOFF, M. D., VON MOLTKE, L. L., COURT, M. H., KOTEGAWA, T., SHADER, R. I. and GREENBLATT, D. J., 2000, Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. Journal of Pharmacology and Experimental Therapeutics, 292, 618–628.
   PubMed Web of Science ®Google Scholar
• PLANT, N. J. and GIBSON, G. G., 2003, Evaluation of the toxicological relevance of CYP3A4 induction. Current Opinion in Drug Discovery and Development, 6, 50–56.
   PubMed Web of Science ®Google Scholar
• SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414–423.
   PubMed Web of Science ®Google Scholar
• TASSANEEYAKUL, W., BIRKETT, D. J., VERONESE, M. E., MuMANus, M. E., TUKEY, R. H., QUATTROCHI, L. C., GELBOIN, H. V. and MINER, J. 0., 1993, Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. Journal of Pharmacology and Experimental Therapeutics, 265, 401–407.
   Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., SCHMIDER, J., DUAN, S. X., WRIGHT, C. E., HARMATZ, J. S. and SHADER, R. I., 1996, Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fiuoxeteine, norfiuoxeteine, and by azole antifungal agents. Journal of Clinical Pharmacology, 36, 783–791.
   PubMed Web of Science ®Google Scholar
• VON MOLTKE, L. L., GREENBLATT, D. J., GRASSI, J. M., GRANDA, B. W., DUAN, S. X., FOGELMAN, S. M., DAILY, J. P., HARMATZ, J. S. and SHADER, R. I., 1998, Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. Journal of Clinical Pharmacology, 38, 106–111.
   PubMed Web of Science ®Google Scholar
• WARRINGTON, J. S., SHADER, R. I., VON MOLTKE, L. L. and GREENBLATT, D. J., 2000, In vitro biotransformation of sildenafil (viagra): identification of human cytochromes and potential drug interactions. Drug Metabolism & Disposition, 28, 392–397.
   PubMed Web of Science ®Google Scholar
• WATKINS, P. B., WRIGHTON, S. A., MAUEL, P., SCHUETS, E. G., MENDEZPICON, G., PARKER, G. A. and GUZELIAN, P. S., 1985, Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences of the United States of America, 82, 6310–6314.
   PubMed Web of Science ®Google Scholar
• WANG, J. S., WEN, X., BACKMAN, J. T., TAAVITSAINEN, P., NEUBONNEN, P. J. and KIVISTO, K. T., 1999, Midazolam a—hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacology & Toxicology, 85, 157–161.
   PubMedGoogle Scholar
• WRIGHTON, S. A., STEVENS, J. C., BECKER, G. W. and VANDENBRANDEN, M., 1993, Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Archives of Biochemistry and Biophysics, 306, 240–245.
   PubMed Web of Science ®Google Scholar
• WRIGHTON, S. A., THUMMEL, K. E., 2000. CYP3A. In R. H. Levy, K. E. Thummel, W. F. Trager, P. D. Hansten and M. Eichelbaum (eds), Metabolic Drug Interactions (Philadelphia: Lippincott Williams & Wilkins), pp. 115–133.
   Google Scholar
• YAMANO, S., TATSUNO, J. and GONZALEZ, F. J., 1990, The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry, 29, 1322–1329.
   PubMed Web of Science ®Google Scholar